Rallybio postpones Avenzo deal closing pending listing approvals
RLYB•Rallybio postponed the merger closing scheduled for November 6, 2026, because listing conditions remain unmet. The previously announced cash distribution may also have a delayed payment date and ex-dividend date.
1. Closing postponed
Rallybio postponed the November 6, 2026, closing of its merger with Avenzo Therapeutics because conditions for listing its shares remain unmet. The parties continue seeking listing approvals under their May 31, 2026, merger agreement.
2. Distribution timing
Funds for the previously announced cash distribution were not deposited with Computershare on November 5 after the postponement. Its previously announced payment date and ex-dividend date may consequently be delayed.
